Cargando…
Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
The incidence of abdominal aortic aneurysm (AAA) in the elderly is increasing year by year with high mortality. Current treatment is mainly through surgery or endovascular intervention, which is not sufficient to reduce future risk. Therefore, we still need to find an effective conservative measure...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Journal of Cardiovascular Pharmacology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079298/ https://www.ncbi.nlm.nih.gov/pubmed/36630701 http://dx.doi.org/10.1097/FJC.0000000000001395 |
_version_ | 1785020699071479808 |
---|---|
author | Jin, Zhongtiao Deng, Hongping Xiong, Sizheng Gao, Ling |
author_facet | Jin, Zhongtiao Deng, Hongping Xiong, Sizheng Gao, Ling |
author_sort | Jin, Zhongtiao |
collection | PubMed |
description | The incidence of abdominal aortic aneurysm (AAA) in the elderly is increasing year by year with high mortality. Current treatment is mainly through surgery or endovascular intervention, which is not sufficient to reduce future risk. Therefore, we still need to find an effective conservative measure as an adjunct therapy or early intervention to prevent AAA progression. Traditional therapeutic agents, such as β-receptor blockers, calcium channel blockers, and statins, have been shown to have limited effects on the growth of AAA. Recently, sodium–glucose cotransport proteins inhibitors (SGLT2is), a new class hypoglycemic drug, have shown outstanding beneficiary effects on cardiovascular diseases by plasma volume reduction, vascular tone regulation, and various unidentified mechanisms. It has been demonstrated that SGLT2i is abundantly expressed in the aorta, and some studies also showed promising results of SGLT2i in treating animal AAA models. This article aims to summarize the recent progress of AAA studies and look forward to the application of SGLT2i in AAA treatment for early intervention or adjunct therapy after surgical repair or stent graft. |
format | Online Article Text |
id | pubmed-10079298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Journal of Cardiovascular Pharmacology |
record_format | MEDLINE/PubMed |
spelling | pubmed-100792982023-04-07 Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms Jin, Zhongtiao Deng, Hongping Xiong, Sizheng Gao, Ling J Cardiovasc Pharmacol Review Article The incidence of abdominal aortic aneurysm (AAA) in the elderly is increasing year by year with high mortality. Current treatment is mainly through surgery or endovascular intervention, which is not sufficient to reduce future risk. Therefore, we still need to find an effective conservative measure as an adjunct therapy or early intervention to prevent AAA progression. Traditional therapeutic agents, such as β-receptor blockers, calcium channel blockers, and statins, have been shown to have limited effects on the growth of AAA. Recently, sodium–glucose cotransport proteins inhibitors (SGLT2is), a new class hypoglycemic drug, have shown outstanding beneficiary effects on cardiovascular diseases by plasma volume reduction, vascular tone regulation, and various unidentified mechanisms. It has been demonstrated that SGLT2i is abundantly expressed in the aorta, and some studies also showed promising results of SGLT2i in treating animal AAA models. This article aims to summarize the recent progress of AAA studies and look forward to the application of SGLT2i in AAA treatment for early intervention or adjunct therapy after surgical repair or stent graft. Journal of Cardiovascular Pharmacology 2023-01-11 /pmc/articles/PMC10079298/ /pubmed/36630701 http://dx.doi.org/10.1097/FJC.0000000000001395 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Review Article Jin, Zhongtiao Deng, Hongping Xiong, Sizheng Gao, Ling Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms |
title | Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms |
title_full | Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms |
title_fullStr | Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms |
title_full_unstemmed | Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms |
title_short | Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms |
title_sort | perspective of sglt2i in the treatment of abdominal aortic aneurysms |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079298/ https://www.ncbi.nlm.nih.gov/pubmed/36630701 http://dx.doi.org/10.1097/FJC.0000000000001395 |
work_keys_str_mv | AT jinzhongtiao perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms AT denghongping perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms AT xiongsizheng perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms AT gaoling perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms |